Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium and Cranial Irradiation in Newly Diagnosed Glioblastoma Multiforme
NCT00022256Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2001
- Primary completion
- Apr 2003
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of motexafin gadolinium in glioblastoma multiforme (GBM), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2001; status: completed.
02
Drugs
motexafin gadolinium
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00022256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022256.